OMTX705 is named as an intervention in 2 current clinical trials in our USA, Spain and Israel registers. 2 are recruiting patients now. All registered phases are Phase 1. The lead sponsor is Oncomatryx Biopharma S.L. The most-studied condition is Pancreatic Adenocarcinoma Metastatic. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
NCT05547321 · ClinicalTrials.gov ↗ · Advanced Solid Tumor
|
Phase 1 | Recruiting | Oncomatryx Biopharma S.L | USA, Spain, Israel |
|
Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma
NCT07377045 · ClinicalTrials.gov ↗ · Pancreatic Adenocarcinoma Metastatic
|
Phase 1 | Recruiting | Oncomatryx Biopharma S.L | USA, Spain, Israel |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing OMTX705. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
Phase 1b/2 Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination with Carboplatin, Pemetrexed and Tislelizumab in Patients with Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer
2025-521989-95-00 · CTIS ↗ · Neoplasms
|
Phase 1 | Authorised | Oncomatryx Biopharma S.L | Spain |
| Lead sponsor | Trials |
|---|---|
| Oncomatryx Biopharma S.L | 2 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 2 | 2 |
| Clinical trials in Spain | 2 | 2 |
| Clinical trials in Israel | 2 | 2 |
| EU register (CTIS) | 1 | — |
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
2 current trials in our USA, Spain and Israel registers name OMTX705 as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in USA, 2 with sites in Spain and 2 with sites in Israel. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Oncomatryx Biopharma S.L. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how OMTX705 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how OMTX705 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists OMTX705 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.